Furthermore, LEA has been reported to be one of the most feared and catastrophic complications in patients with diabetic foot disorders. [3] [4] [5] As a result of these complications and increased risk of mortality, patients with diabetic foot disease often have underlying concerns that they may not manifest outwardly. 6, 7 When confronted with the possibility of undergoing major LEA, patients with diabetic foot disease are burdened with one of the most difficult decisions and stressful periods of their life. 4 The aim of this study was to identify the most-feared complications of diabetes reported in a cohort of patients with DM, comparing those with diabetic foot pathology to those without diabetic foot pathology. Our hypothesis was that patients with diabetic foot pathology would fear major LEA more than diabetic patients without foot complications.
Patients/Materials and Methods
This prospective study was approved by our institutional review board and included patients who presented to 2 academic foot and ankle programs. The inclusion criteria included patients with type 1 or 2 DM, aged 18 years and older, who were evaluated for foot disorders from July 2013 until January 2015. We sought to determine the frequency of patients ranking major LEA as their most-feared complication of DM in comparison to blindness, death, diabetic foot infection (DFI), or ESRD requiring dialysis. These particular complications of diabetes were chosen by the senior author based on the common complications seen in patients with established diabetic foot disease. In addition, recent studies addressing the fears of patients with type 1 and type 2 diabetes listed amputation, blindness, and renal disease as major concerns of patients. [6] [7] We further categorized the study group patients based on their diabetic foot pathology such as DFU, CN, foot infection, or neuropathic fractures and dislocations. The control group comprised diabetic patients who presented with common non-diabetesrelated foot pathology (tendonitis, bunions, sprains and strains, flatfeet, etc) and/or diabetic patients who underwent routine foot screening without any subjective complaints. All patients in the study were provided with a list of 5 complications of DM (major LEA, blindness, death from heart attack or stroke, foot infection, or kidney failure requiring dialysis) and asked to rank them in order of their most-to least-feared complication. The most-feared complication received a score of 1 and the least feared a score of 5. Demographic data such as age, BMI, gender, duration of DM, type of DM, and insulin use were recorded. All patients had a foot examination, and the presence of peripheral artery disease, neuropathy, CN, and DFU was recorded. Neuropathy was determined by calculating the Michigan Neuropathy Screening Index and was defined as a score ≥2.5.
8 Both the dorsalis pedis and posterior tibial pulses were examined bilaterally, and the vascular examination was considered abnormal if 2 or more pulses were absent.
Descriptive statistical analyses were conducted to determine frequencies (%) of categorical variables and the median and 25th to 75th interquartile range (IQR) of continuous variables. Frequency distributions of categorical variables between individuals with and without diabetic foot disease were compared using Pearson's χ 2 tests or Fisher's exact tests, when appropriate. The Mann-Whitney tests were used to determine differences between groups for continuous data. All tests were conducted with a significance level of .05. We also evaluated the risk factors associated with mortality, assessing both categorical and continuous variables
Results
A total of 461 patients were enrolled in this study and included 254 patients without diabetic foot complications and 207 patients with diabetic foot problems. The mean age of our patients was 60.2 (±10.7) years, and 230 of 461 patients (49.9%) were male. The majority of our patients had type 2 DM (n = 411, 89.2%), used insulin (n = 295, 64.0%), were obese (n = 319, 69.2%), and had peripheral neuropathy (n = 348, 75.5%). The median duration of DM was 10 years (25th-75th IQR = 6-20); the median BMI was 32.5 kg/m 2 (25th-75th IQR = 28.6-38.5); and the median Michigan Neuropathy Screening Index was 5 (IQR = 2-7). Overall, in our cohort of 461 patients, the number of patients ranking each complication of diabetes as their greatest fear (Table 1) was blindness (n = 161, 34.9%), death (n = 129, 28.0%), amputation (n = 108, 23.4%), ESRD requiring dialysis (n = 48, 10.4%), and DFI (n = 15, 3.3%).
Patients Without Diabetic Foot Disease
In patients without established diabetic foot disease, blindness (35.4%) and death (33.9%) were most commonly reported as the greatest feared complications of DM (Table 1) . Patients without diabetic foot disease were significantly less likely to rank major LEA as their greatest fear compared with blindness (odds ratio
[OR] = 0.36; 96% CI = 0.24 to 0.55; P < .0001) and death (OR = 0.39; 95% CI = 0.26 to 0.59; P < .0001). Patients were significantly more likely to rank amputation as their greatest fear compared with experiencing a DFI (OR = 12.38; 95% CI = 4.67 to 32.6; P < .0001). There was no significant difference when comparing amputation and ESRD requiring dialysis (OR = 1.374; 95% CI = 0.8266 to 2.27; P = .26).
Patients With Diabetic Foot Disease
In patients with diabetic foot disease, blindness (34.3%) and LEA (31.9%) were most commonly reported as their mostfeared complication of DM (Table 1) . There was no significant difference when comparing LEA and blindness as the greatest fear (OR = 0.90; 96% CI = 0.59 to 1.36; P = .68). Patients with diabetic foot disease were significantly more likely to rank LEA as their greatest fear when compared to death (OR = 1.79; 96% CI = 1.13 to 2.81; P = .01), DFI (OR = 8.34; 96% CI = 4.369 to 16.08; P < .0001) and ESRD requiring dialysis (OR = 5.59; 96% CI = 3.079 to 9.907; P < .00010.
Comparison of Patients With and Without Diabetic Foot Disease
When comparing patients with and without diabetic foot disease, no significant differences were observed with regard to their fear of blindness, DFI, or ESRD requiring dialysis ( Figure  1 ). Patients with diabetic foot disease (61 of 207, 31.9%) were 136% more likely (OR = 2.36; 95% CI = 1.51-3.70; P = .002) to rank major LEA as their greatest fear when compared with diabetic patients without foot disease (42 of 254, 16.5%) and 49% less likely (OR = 0.51; 95% CI = 0.34-0.79; P = .002) to rank death as their greatest fear compared with patients without diabetic foot disease (Figure 1 ).
Demographic data that were significantly associated with ranking major LEA as the greatest fear (Table 2) were duration of DM ≥10 years (OR = 6.0; 95% CI = 3.8-9.6; P < .0001), insulin use (OR = 46.0; 95% CI = 13.0-192.1; P < .0001), diabetic foot disease (OR = 2.4; 95% CI = 1.5-3.7; P = .0002), and peripheral neuropathy (OR = 49.7; 95% CI = 9.2-504.5; P < .0001). Gender, age ≥65 years, type 2 DM, and obesity were not significantly associated with ranking LEA as the greatest fear (Table 2) .
Discussion
Complications in patients with DM such as amputation, 9 blindness, 10 ESRD, 11 and foot infections 12 Approximately 33% of these patients stated that the fear of amputation frightened them the most, and 25% identified blindness as their greatest fear. 7 Patients with type 1 DM list amputation, cardiovascular disease, neuropathy, and stroke as their greatest fears, whereas patients with type 2 DM fear retinopathy, amputation, nephropathy, neuropathy, and stroke. 6 It appears that patients with type 1 and type 2 DM fear long-term consequences of DM more than acute complications such as hypoglycemia, coma, insulin shock, or hyperglycemia. 6 Some authors have opined that major LEA is catastrophic and one of the most-feared complications of DM. To the best of our knowledge, these opinions are not based on any scientific study. This study demonstrated that patients with diabetic foot complications were significantly more likely to rank LEA as their greatest fear when compared with death, DFI, or ESRD requiring dialysis. No difference was observed when comparing LEA and blindness as the greatest fears. Once patients develop a diabetic foot problem, the risk of LEA rises dramatically and, apparently, so does the fear of LEA. Patients with diabetic foot disease were 79% more likely (OR = 1.79) to rank LEA as their greatest fear compared with death, and 136% more likely (OR = 2.36) to rank LEA as the greatest fear when compared with patients without diabetic foot disease.
Both groups of diabetic patients (those with and without foot complications) were more likely to rank blindness as their greatest fear when compared with other complications (35.4% in patients This study has limitations that merit discussion. Although the choice of LEA, blindness, death, foot infection, and ESRD as fears was based on commonly reported complications of DM, these choices were arbitrarily made by the Comparison of the most-feared complications of diabetes between patients with and without diabetic foot disease.
Abbreviations: OR, odds ratio; DFI, diabetic foot infection; ESRD, end-stage renal disease. senior author and potentially represent bias. The decision to evaluate these 5 complications was made based on the common comorbidities experienced by diabetic patients who have microvascular and macrovascular disease. Although patients' fear has been evaluated in diabetic patients in general, to the best of our knowledge, we are not aware of any validated studies that have addressed these fears in patients with established diabetes-related foot complications. 6, 7 Consequently, we acknowledge that selection and interviewer bias is potentially present because the senior author designed the study and recorded the choices. Readers of this article should interpret our results with the caveat that our assessment of fears in patients with diabetic foot disease has not been validated. The design of the study was potentially flawed because patients were asked to rank their fears from the greatest to the least (1) (2) (3) (4) (5) . This methodology flaw resulted in variables that were neither continuous nor ordinal. Consequently, we were unable to compare the median score (ie, 1-5) between variables. For example, we are unable to answer the question if the median ranking of LEA was significantly different from the median rankings for blindness, death, foot infection, or ESRD. To address this flaw, we are planning a prospective study using a Likert scale that poses the following question for each of the 5 variables. How much do you fear major LEA (or blindness, death, DFI, or ESRD): no fear, a little fear, moderate fear, or severe fear. Identifying the most-feared complications of DM in patients with diabetic foot pathology provides an opportunity to educate patients and assist in self-management techniques to reduce the possibility of complications. For instance, patients who fear major LEA and foot infection potentially are more receptive when given advice to check their feet daily and to wear shoes at home. 7 We also observed during our data collection that some patients, both in the cohorts with and without diabetic foot disease, were unaware of some of the potential complications, such as blindness and kidney failure. Educating patients on the importance of glycemic control and routine screening for microvascular disease (retinal, renal, and neurological) takes very little time, and patients are usually very receptive to this guidance from their "diabetic foot doctor." This vital educational session can also be provided by residents in training and advanced practice providers such as nurses and physician assistants. Because it appears that diabetic patients fear long-term complications of DM (amputation, cardiovascular disease, nephropathy, neuropathy, and retinopathy), education on the importance of long-term preventive care is paramount in high-risk patients. 7 Because the pathophysiology of diabetic foot complications is similar to retinopathy, nephropathy, and neuropathy, the results of this study have changed the way we educated patients. Previously, we concentrated on discussing the importance of glycemic control and routine foot care as it related to preventing lower-extremity complications. We have found that patients respond more positively to a combined educational approach that addresses not only foot care, but prevention of other fears such as blindness, kidney disease, and cardiovascular disease.
In conclusion, we found that patients with diabetic foot pathology fear major LEA more than death, foot infection, or ESRD. Blindness and major LEA were most frequently cited as the most-feared complications of DM in this patient population. Variables that were associated with ranking LEA as the greatest fear were the presence of a diabetes-related foot complication, duration of DM ≥10 years, insulin use, and the presence of peripheral neuropathy. Despite the acknowledged limitations, as noted in the discussion, this study provides guidance to health care providers on the potential fears that diabetic foot patients experience on a daily basis.
